

RG7112

Catalog No: tcsc0330



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

939981-39-2

Formula:

$C_{38}H_{48}Cl_2N_4O_4S$

Pathway:

Apoptosis

Target:

MDM-2/p53

Purity / Grade:

>98%

Solubility:

H₂O :

Alternative Names:

RO5045337

Observed Molecular Weight:
727.78


Product Description

RG7112 is the first clinical and orally available **MDM-2/p53** inhibitor designed to occupy the p53-binding pocket of MDM2, with the **K_d** value of 11 nM.

IC50 & Target: K_d: 11 nM (MDM2)^[1]

In Vitro: RG7112 (2.5μM) is more active against proliferation of liposarcoma cells, and especially those with wild-type p53. Treatment of cells with either Nutlin-3A or RG7112 induces cell-cycle arrest and apoptosis in the p53-WT cell line 93T449. RG7112 treatment reduces cell viability much more than Nutlin-3A in HT-1080, SW684, 93T449, and SW872 cells^[1]. RG7112 shows potent antitumor activity against a panel of solid tumor cell lines. Treatment of cancer cells expressing wild-type p53 with RG7112 activates the p53 pathway, leading to cell-cycle arrest and apoptosis^[2].

In Vivo: RG7112 is highly synergistic with androgen deprivation in LNCaP xenograft tumors. RG7112 (25-200 mg/kg, p.o.) to human xenograft-bearing mice at nontoxic concentrations causes dose-dependent changes in proliferation/apoptosis biomarkers as well as tumor inhibition and regression^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!